Comparing disease-specific and generic quality of life measures in patients with schizophrenia

Seow, Lee Seng Esmond; Tan, Tee Hng; Abdin, Edimansyah; Chong, Siow Ann; Subramaniam, Mythily

doi:10.1016/j.psychres.2019.01.034

Cited by 15 publications

(11 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, unlike generic measures, condition-specific measures are not recommended for evaluations across different conditions. 31 Although a generic measure, the CHU-9D may be more likely than the EQ-5D-Y and HUI to capture dimensions of HRQoL that are important to CYP with CP. In particular, the CHU-9D includes more questions about psychological difficulties and pain, which are associated with QoL among CYP with CP.…”

Section: Discussionmentioning

confidence: 99%

Comparison of the CHU-9D and the EQ-5D-Y instruments in children and young people with cerebral palsy: a cross-sectional study

et al. 2020

View full text Add to dashboard Cite

ObjectiveTo compare the performance of the EuroQol 5D youth (EQ-5D-Y) and child health utility 9D (CHU-9D) for assessing health-related quality of life (HRQoL) in children and young people (CYP) with cerebral palsy (CP).DesignCross-sectional study.SettingEngland.ParticipantsSixty-four CYP with CP aged 10–19 years in Gross Motor Function Classification System (GMFCS) levels I–III.Main outcome measuresMissing data were examined to assess feasibility. Associations between utility values and individual dimensions on each instrument were examined to assess convergent validity. Associations between utility values and GMFCS level were examined to assess known-group differences.ResultsMissing data were <5% for both instruments. Twenty participants (32.3%) and 11 participants (18.0%) reported full health for the EQ-5D-Y and CHU-9D, respectively. There was poor agreement between utilities from the two instruments (intraclass correlation coefficient=0.62; 95% limits of agreement −0.58 to 0.29). Correlations between EQ-5D-Y and CHU-9D dimensions were weak to moderate (r=0.25 to 0.59). GMFCS level was associated with EQ-5D-Y utility values but not CHU-9D utility values.ConclusionThe EQ-5D-Y and CHU-9D are feasible measures of HRQoL in CYP with CP. However, the two instruments demonstrate poor agreement and should not be used to measure and value HRQoL in CYP with CP interchangeably. We propose that the CHU-9D may be preferable to use in this population as it assesses concepts that influence HRQoL among CYP with CP and provides less extreme utility values than the EQ-5D-Y.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of the CHU-9D and the EQ-5D-Y instruments in children and young people with cerebral palsy: a cross-sectional study

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Concordance: None (No) = significant impact on quality of life with disease/condition specific tool, but no change or the opposite impact with generic tool (or vice versa); Moderate = quality of life impact was scored in the same direction with both tools, but statistically significant with only one of them; Strong = results fully aligned (significant/ non-significant impact in same direction) disease/condition. Several approaches have been taken to improve the accurate assessment of HRQoL, including: the parallel use of generic and disease/condition tools [15,16]; using mapping algorithms from disease/ condition-specific tools to generic tools [10]; tailoring standard items to specific diseases/conditions [17]; and use of bolt-on items to generic questionnaires [10]. Despite these approaches, the pertinent question remainswhat is acceptable accuracy for a HRQoL tool?…”

Section: Rare Diseasementioning

confidence: 99%

Neutral theory: applicability and neutrality of using generic health-related quality of life tools in diseases or conditions where specific tools are available

Jandhyala

2021

BMC Med Res Methodol

View full text Add to dashboard Cite

Background Health-related quality of life (HRQoL) tools are limited by the indicators included in the construct and variation in interpretation by different researchers. Neutral Theory describes the ideal construct that includes all relevant indicators and, therefore, complete accuracy, or neutrality. Neutral Theory can thereby provide the framework to develop or test constructs. To assess the application of Neutral Theory, the neutrality of generic tools (SF-36 and EQ-5D) at measuring HRQoL was compared to disease/condition-specific tools, with the latter considered surrogates for the Neutral construct. Methods Full descriptions of all disease/condition-specific HRQoL tools published on PubMed (to 01-Jul-19) were sourced. For each tool, the number of items with and without a direct match within the SF-36 and EQ-5D was recorded and the sensitivity/specificity calculated. Results The SF-36 and EQ-5D did not achieve a sensitivity/specificity both > 50% against any of the 163 disease/condition-specific tools identified. At 20% prevalence of poor HRQoL, the false positive rate (FPR) was > 75% for all but two tools against the SF-36 and six tools against the EQ-5D. Increasing poor HRQoL to 80%, 47 tools for the SF-36 and 48 tools for the EQ-5D had a FPR < 50%. For rare disease tools (< 1/2000 population; n = 17), sensitivity/specificity ranged from 0 to 40%/5–31% for the SF-36 and 0–22%/29–100% for the EQ-5D. For non-rare (n = 75) and symptom-specific tools (n = 71) sensitivity/specificity was: 0–100%/0–100% (SF-36) and 0–50%/0–100% (EQ-5D); and 0–60%/0–19% (SF-36) and 0–25%/0–100% (EQ-5D), respectively. No concordance was recorded for 18% (2/11) of results from studies of rare disease tools versus the SF-36 (no data vs EQ-5D). For non-rare, disease-specific tools, results were discordant for 30% (25/84) and 35% (23/65) of studies against the SF-36 and EQ-5D, respectively. For symptom-specific tools, corresponding results were 36% (24/66) and 16% (5/31). Conclusions Generic HRQoL tools appear poorly correlated with disease/condition-specific tools, which indicates that adoption of Neutral Theory in the development and assessment of HRQoL tools could improve their relevance, accuracy, and utility in economic evaluations of health interventions.

show abstract

“…There is currently a debate about which measurements better reflect the HRQoL of patients with schizophrenia 4. HRQoL can be measured either with generic or with condition specific HRQoL scales.…”

Section: Introductionmentioning

confidence: 99%

<p>Correlation of Health-Related Quality of Life in Clinically Stable Outpatients with Schizophrenia</p>

Domènech

Pastore

Altamura

et al. 2019

NDT

View full text Add to dashboard Cite

BackgroundGeneric health-related quality of life (HRQoL) scales are increasingly being used to assess the effects of new treatments in schizophrenia. The objective of this study is to better understand the usefulness of generic and condition specific HRQoL scales in schizophrenia by analyzing their correlates.MethodsData formed part of the Pattern study, an international observational study among 1379 outpatients with schizophrenia. Patients were evaluated with the Mini International Neuropsychiatric Inventory, the Clinical Global Impression-Schizophrenia (CGI-SCH) Scale and the Positive and Negative Syndrome Scale (PANSS) and reported their HRQoL using the Schizophrenia Quality of Life Scale (SQLS), the Short Form-36 (SF-36), and the EuroQol-5 Dimension (EQ-5D). The two summary values of the SF-36 (the Mental Component Score and the Physical Component Score, SF-36 MCS and SF-36 PCS) were calculated.ResultsHigher PANSS positive dimension ratings were associated with worse HRQoL for the SQLS, EQ-5D VAS, SF-36 MCS, and SF-36 PCS. Higher PANSS negative dimension ratings were associated with worse HRQoL for the EQ-5D VAS, SF-36 MCS, and SF-36 PCS, but not for the SQLS or the EQ-5D tariff. PANSS depression ratings were associated with lower HRQoL in all the scales. There was a high correlation between the HRQoL scales. However, in patients with more severe cognitive/disorganized PANSS symptoms, the SQLS score was relatively higher than the EQ-5D tariff and SF-36 PCS scores.ConclusionThis study has shown substantial agreement between three HRQoL scales, being either generic or condition specific. This supports the use of generic HRQoL measures in schizophrenia.Clinicaltrials.gov identifierNCT01634542 (July 6, 2012, retrospectively registered).

show abstract

Comparing disease-specific and generic quality of life measures in patients with schizophrenia

Cited by 15 publications

References 35 publications

Comparison of the CHU-9D and the EQ-5D-Y instruments in children and young people with cerebral palsy: a cross-sectional study

Comparison of the CHU-9D and the EQ-5D-Y instruments in children and young people with cerebral palsy: a cross-sectional study

Neutral theory: applicability and neutrality of using generic health-related quality of life tools in diseases or conditions where specific tools are available

<p>Correlation of Health-Related Quality of Life in Clinically Stable Outpatients with Schizophrenia</p>

Contact Info

Product

Resources

About